Clinical Trials Browser

Phase 2 × Breast Neoplasms × Cetuximab × Clear all

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2 Active not recruiting

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT00248287 2025-01-29

CA225200

Phase 2 Active not recruiting

154 enrolled 12 charts

Breast Neoplasms

NCT01097642 2021-09-22

ICE

Phase 2 Completed

40 enrolled 11 charts

Breast Neoplasms

NCT00232505 2017-06-28

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Phase 2 Completed

112 enrolled 13 charts

Breast Neoplasms

NCT00275041 2016-12-13

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00633464 2016-03-10

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Phase 2 Completed

79 enrolled 15 charts

Breast Neoplasms

NCT00600249 2014-03-20

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Phase 2 Completed

Breast Neoplasms

NCT00463788 2014-02-13

BALI-1

Phase 2 Completed

181 enrolled 15 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms